1. Home
  2. CPZ vs SABS Comparison

CPZ vs SABS Comparison

Compare CPZ & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Long/Short Equity & Dynamic Income Trust

CPZ

Calamos Long/Short Equity & Dynamic Income Trust

HOLD

Current Price

$12.82

Market Cap

272.9M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.93

Market Cap

288.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPZ
SABS
Founded
N/A
2014
Country
United States
United States
Employees
N/A
86
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.9M
288.8M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CPZ
SABS
Price
$12.82
$3.93
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
75.7K
851.4K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.41
$1.67
52 Week High
$16.82
$6.60

Technical Indicators

Market Signals
Indicator
CPZ
SABS
Relative Strength Index (RSI) 42.52 57.64
Support Level $12.73 $3.68
Resistance Level $13.17 $4.09
Average True Range (ATR) 0.23 0.23
MACD 0.03 0.07
Stochastic Oscillator 55.76 70.33

Price Performance

Historical Comparison
CPZ
SABS

About CPZ Calamos Long/Short Equity & Dynamic Income Trust

Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: